Amarantus Biosci Inc (AMBS) 0.0774 $AMBS
Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia
GlobeNewswire - Tue Feb 10, 6:25AM CST
-- Eltoprazine demonstrated significant beneficial anti-dyskinesia effect at 5 and 7.5 mg doses, with no reduction of levodopa efficacy
Adamas' Lead Drug Targets Parkinson's Dyskinesia
Michael Hagan - at Seeking Alpha - Tue Feb 03, 4:53PM CST
IPXL: 39.51 (+0.69), ADMS: 16.98 (+0.03), ACOR: 36.14 (-0.51), NDRM: 10.76 (+0.22)
Amarantus to Present at the 17th Annual BIO CEO & Investor Conference on February 10, 2015
GlobeNewswire - Tue Feb 03, 7:05AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it will be presenting at the 17th Annual BIO CEO & Investor Conference being held February 9-10, 2015, at the Waldorf Astoria in New York, New York.
Amarantus BioScience Holdings, Inc. - "Amarantus Diagnostics"
ACCESSWIRE - Wed Jan 28, 7:43AM CST
NEW YORK, NY / ACCESSWIRE / January 28, 2015 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's President and CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Forms Alzheimer's Disease Diagnostics Scientific Advisory Board
GlobeNewswire - Thu Jan 22, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has established an Alzheimer's disease Diagnostics Scientific Advisory Board (SAB) and appointed three internationally-renowned specialists in Alzheimer's disease (AD) and neurological disorders, Paula T. Trzepacz, M.D., Jeffrey L. Cummings, M.D., Sc.D., and Robert A. Stern, Ph.D., as its first members. The company expects to expand the SAB during the first half of 2015.
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
GlobeNewswire - Thu Jan 15, 5:15AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of novel diagnostic tests in neurology and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has executed a one-year, exclusive option agreement with Georgetown University to enter into a license for the patent rights related to certain blood based biomarkers for memory loss that Georgetown University and University of Rochester jointly own. Amarantus will be required to achieve timely milestones including providing Georgetown with development and commercialization plans for the biomarkers, share information related to Amarantus' diagnostic assets, CLIA validation of biomarkers, recruitment of a senior executive to lead Amarantus' diagnostics division and other requirements as defined in the agreement.
Amarantus Announces Positive Data From 140 Subject LP-002 Clinical Study of LymPro Test(R) Confirming Statistically Significant Markers for Alzheimer's
GlobeNewswire - Thu Jan 15, 5:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the development of diagnostics for neurology and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, reported positive top-line results of its LP-002 study of the Lymphocyte Proliferation Test (LymPro Test) blood diagnostic for Alzheimer's disease (AD). Results from the 140-subject study demonstrated that multiple individual biomarkers achieved statistically significant results to correctly identify patients with AD from healthy controls. The company recently completed 'Fit-for-Purpose' assay validation for LymPro at Icon Central Laboratories in Farmingdale, NY, enabling the assay to be offered to the pharmaceutical industry for evaluation in therapeutic Alzheimer's clinical trials. Biomarker services using LymPro Test biomarker data are now available to the pharmaceutical industry for Investigational Use Only (IUO) in pharmaceutical therapeutic clinical development programs.
Amarantus buys molecular diagnostics company
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 3:38PM CST
Amarantus to Present at Noble Financial Capital Markets' Eleventh Annual Investor Conference
GlobeNewswire - Tue Jan 13, 8:32AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in neurology and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced today that its President & CEO, Gerald E. Commissiong, will be presenting at the Noble Financial Capital Markets' Eleventh Annual Investor Conference being held January 18 - 21, 2015, in Sandpiper Bay, FL.
Amarantus Announces Acquisition of Specialized Neuro-Diagnostics Company, DioGenix
GlobeNewswire - Mon Jan 12, 8:16AM CST
-- Lead Product MSPrecise: Clinically Validated, First-In-Class Next-Generation Sequencing (NGS) Assay that Identifies Multiple Sclerosis (MS) at First Clinical Presentation
Amarantus to Participate in the Eighth Annual OneMedForum Conference on January 12 - 13, 2015
GlobeNewswire - Thu Jan 08, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it will participate in the Eighth Annual OneMedForum on January 12 - 13, 2015, at the Marriott Marquis in San Francisco, CA.
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 37.22 (+0.27), LPCN: 5.91 (+0.40), EPRS: 7.67 (+0.67), DEPO: 18.38 (+0.20), ASPX: 65.76 (+2.76), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Amarantus to Present LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R) at Biotech Showcase 2015 Conference on January 14, 2015
GlobeNewswire - Mon Dec 29, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced it will be presenting a corporate overview including top-line results of its expanded LP-002 study of the Lymphocyte Proliferation Test (LymPro Test) blood diagnostic for Alzheimer's disease (AD) at Biotech Showcase 2015. Gerald E. Commissiong, President & CEO of Amarantus, will present on Wednesday, January 14, 2015 at the Parc 55 Wyndham Union Square in San Francisco, CA.
Amarantus' MANF an Orphan Drug for degenerative eye disease
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:41PM CST
Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
GlobeNewswire - Tue Dec 23, 3:00PM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that the U.S. Food and Drug Administration (FDA) has granted the company's investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) orphan drug designation for the treatment of Retinitis Pigmentosa (RP). RP refers to a group of inherited diseases causing retinal degeneration often leading to blindness.
Amarantus BioScience Holdings, Inc. - "Amarantus Diagnostics: Launching our First Product in the Neurodiagnostics Marketâ??"
ACCESSWIRE - Mon Dec 22, 10:25AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus anticipates additional USD2.0m through second closing of Series E Preferred financing
M2 - Mon Dec 22, 6:38AM CST
Biotechnology company Amarantus BioScience Holdings (Other OTC:AMBS) said on Friday that it expects to raise an additional USD2.0m through the issue of shares of Series E preferred stock.
Amarantus Commences Launch of Proprietary Alzheimer's Blood Diagnostic LymPro Test(R) to Pharmaceutical Industry for Use in Clinical Trials
GlobeNewswire - Mon Dec 22, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced the launch of the company's LymPro Test, a leading, proprietary Alzheimer's blood diagnostic, to the pharmaceutical industry for investigational use in clinical development programs. The commercialization of LymPro follows the successful completion of the requisite 'Fit-for-Purpose' assay validation conducted at Icon Central Laboratories.
Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF
GlobeNewswire - Fri Dec 19, 6:35AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has applied to the U.S. Food & Drug Administration (FDA) for Orphan Drug Designation for its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) as a treatment for retinal artery occlusion (RAO). RAO is a blockage of the blood supply to the retina which causes severe and sudden loss of vision.
Amarantus Announces Second Closing of Series E Preferred Financing
GlobeNewswire - Fri Dec 19, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has entered into definitive agreements to raise an additional $2.0 million under its previously announced transaction to issue shares of Series E Preferred Stock (the "Series E"
, bringing the total capital raised to $5.0 million. The second closing was led by International Infusion.
Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia
GlobeNewswire - Tue Feb 10, 6:25AM CST
-- Eltoprazine demonstrated significant beneficial anti-dyskinesia effect at 5 and 7.5 mg doses, with no reduction of levodopa efficacy
Adamas' Lead Drug Targets Parkinson's Dyskinesia
Michael Hagan - at Seeking Alpha - Tue Feb 03, 4:53PM CST
IPXL: 39.51 (+0.69), ADMS: 16.98 (+0.03), ACOR: 36.14 (-0.51), NDRM: 10.76 (+0.22)
Amarantus to Present at the 17th Annual BIO CEO & Investor Conference on February 10, 2015
GlobeNewswire - Tue Feb 03, 7:05AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it will be presenting at the 17th Annual BIO CEO & Investor Conference being held February 9-10, 2015, at the Waldorf Astoria in New York, New York.
Amarantus BioScience Holdings, Inc. - "Amarantus Diagnostics"
ACCESSWIRE - Wed Jan 28, 7:43AM CST
NEW YORK, NY / ACCESSWIRE / January 28, 2015 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's President and CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Forms Alzheimer's Disease Diagnostics Scientific Advisory Board
GlobeNewswire - Thu Jan 22, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has established an Alzheimer's disease Diagnostics Scientific Advisory Board (SAB) and appointed three internationally-renowned specialists in Alzheimer's disease (AD) and neurological disorders, Paula T. Trzepacz, M.D., Jeffrey L. Cummings, M.D., Sc.D., and Robert A. Stern, Ph.D., as its first members. The company expects to expand the SAB during the first half of 2015.
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
GlobeNewswire - Thu Jan 15, 5:15AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of novel diagnostic tests in neurology and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has executed a one-year, exclusive option agreement with Georgetown University to enter into a license for the patent rights related to certain blood based biomarkers for memory loss that Georgetown University and University of Rochester jointly own. Amarantus will be required to achieve timely milestones including providing Georgetown with development and commercialization plans for the biomarkers, share information related to Amarantus' diagnostic assets, CLIA validation of biomarkers, recruitment of a senior executive to lead Amarantus' diagnostics division and other requirements as defined in the agreement.
Amarantus Announces Positive Data From 140 Subject LP-002 Clinical Study of LymPro Test(R) Confirming Statistically Significant Markers for Alzheimer's
GlobeNewswire - Thu Jan 15, 5:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the development of diagnostics for neurology and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, reported positive top-line results of its LP-002 study of the Lymphocyte Proliferation Test (LymPro Test) blood diagnostic for Alzheimer's disease (AD). Results from the 140-subject study demonstrated that multiple individual biomarkers achieved statistically significant results to correctly identify patients with AD from healthy controls. The company recently completed 'Fit-for-Purpose' assay validation for LymPro at Icon Central Laboratories in Farmingdale, NY, enabling the assay to be offered to the pharmaceutical industry for evaluation in therapeutic Alzheimer's clinical trials. Biomarker services using LymPro Test biomarker data are now available to the pharmaceutical industry for Investigational Use Only (IUO) in pharmaceutical therapeutic clinical development programs.
Amarantus buys molecular diagnostics company
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 3:38PM CST
Amarantus to Present at Noble Financial Capital Markets' Eleventh Annual Investor Conference
GlobeNewswire - Tue Jan 13, 8:32AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in neurology and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced today that its President & CEO, Gerald E. Commissiong, will be presenting at the Noble Financial Capital Markets' Eleventh Annual Investor Conference being held January 18 - 21, 2015, in Sandpiper Bay, FL.
Amarantus Announces Acquisition of Specialized Neuro-Diagnostics Company, DioGenix
GlobeNewswire - Mon Jan 12, 8:16AM CST
-- Lead Product MSPrecise: Clinically Validated, First-In-Class Next-Generation Sequencing (NGS) Assay that Identifies Multiple Sclerosis (MS) at First Clinical Presentation
Amarantus to Participate in the Eighth Annual OneMedForum Conference on January 12 - 13, 2015
GlobeNewswire - Thu Jan 08, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it will participate in the Eighth Annual OneMedForum on January 12 - 13, 2015, at the Marriott Marquis in San Francisco, CA.
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 37.22 (+0.27), LPCN: 5.91 (+0.40), EPRS: 7.67 (+0.67), DEPO: 18.38 (+0.20), ASPX: 65.76 (+2.76), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Amarantus to Present LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R) at Biotech Showcase 2015 Conference on January 14, 2015
GlobeNewswire - Mon Dec 29, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced it will be presenting a corporate overview including top-line results of its expanded LP-002 study of the Lymphocyte Proliferation Test (LymPro Test) blood diagnostic for Alzheimer's disease (AD) at Biotech Showcase 2015. Gerald E. Commissiong, President & CEO of Amarantus, will present on Wednesday, January 14, 2015 at the Parc 55 Wyndham Union Square in San Francisco, CA.
Amarantus' MANF an Orphan Drug for degenerative eye disease
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:41PM CST
Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
GlobeNewswire - Tue Dec 23, 3:00PM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that the U.S. Food and Drug Administration (FDA) has granted the company's investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) orphan drug designation for the treatment of Retinitis Pigmentosa (RP). RP refers to a group of inherited diseases causing retinal degeneration often leading to blindness.
Amarantus BioScience Holdings, Inc. - "Amarantus Diagnostics: Launching our First Product in the Neurodiagnostics Marketâ??"
ACCESSWIRE - Mon Dec 22, 10:25AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus anticipates additional USD2.0m through second closing of Series E Preferred financing
M2 - Mon Dec 22, 6:38AM CST
Biotechnology company Amarantus BioScience Holdings (Other OTC:AMBS) said on Friday that it expects to raise an additional USD2.0m through the issue of shares of Series E preferred stock.
Amarantus Commences Launch of Proprietary Alzheimer's Blood Diagnostic LymPro Test(R) to Pharmaceutical Industry for Use in Clinical Trials
GlobeNewswire - Mon Dec 22, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced the launch of the company's LymPro Test, a leading, proprietary Alzheimer's blood diagnostic, to the pharmaceutical industry for investigational use in clinical development programs. The commercialization of LymPro follows the successful completion of the requisite 'Fit-for-Purpose' assay validation conducted at Icon Central Laboratories.
Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF
GlobeNewswire - Fri Dec 19, 6:35AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has applied to the U.S. Food & Drug Administration (FDA) for Orphan Drug Designation for its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) as a treatment for retinal artery occlusion (RAO). RAO is a blockage of the blood supply to the retina which causes severe and sudden loss of vision.
Amarantus Announces Second Closing of Series E Preferred Financing
GlobeNewswire - Fri Dec 19, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has entered into definitive agreements to raise an additional $2.0 million under its previously announced transaction to issue shares of Series E Preferred Stock (the "Series E"
, bringing the total capital raised to $5.0 million. The second closing was led by International Infusion. 
